 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA Taysha, a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system CNS in both rare and large patient populations, today announced that it will report its financial results for full-year ended December 31, 2020, and host a corporate update conference call and webcast on Wednesday, March 3, 2 